Stay updated on Induction TPN, Nivolumab, Radiation in Larynx/Hypopharynx Clinical Trial
Sign up to get notified when there's something new on the Induction TPN, Nivolumab, Radiation in Larynx/Hypopharynx Clinical Trial page.

Latest updates to the Induction TPN, Nivolumab, Radiation in Larynx/Hypopharynx Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page footer shows a new site revision: v3.3.2, replacing the previous v3.3.1. This appears to be a minor administrative update with no impact on the study details, eligibility criteria, or content presented on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check24 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1; the visible study details and criteria appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check32 days agoChange DetectedThe government funding lapse notice has been removed from the page, and the study details and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check46 days agoChange DetectedNo significant changes were detected between the two screenshots; the page content and study details appear unchanged.SummaryDifference0.4%

- Check74 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference3%

- Check82 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0. This signals a software update; no other content changes are indicated.SummaryDifference0.1%

Stay in the know with updates to Induction TPN, Nivolumab, Radiation in Larynx/Hypopharynx Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Induction TPN, Nivolumab, Radiation in Larynx/Hypopharynx Clinical Trial page.